Order Article Reprints

Hirsch A, Scapa E, Fliss-Isakov N, Tulchinsky H, Itzkowitz E, Kariv Y, Ron Y, Yanai H, White I, Yassin S, et al. Early Initiation of Adalimumab Significantly Diminishes Postoperative Crohn’s Disease Endoscopic Recurrence and Is Superior to 6-Mercaptopurine Therapy: An Open-Label, Randomized Controlled Study. Journal of Clinical Medicine. 2023; 12(24):7600. https://doi.org/10.3390/jcm12247600

Hirsch, Ayal, Erez Scapa, Naomi Fliss-Isakov, Hagit Tulchinsky, Eran Itzkowitz, Yehuda Kariv, Yulia Ron, Henit Yanai, Ian White, Sharief Yassin, and et al. 2023. "Early Initiation of Adalimumab Significantly Diminishes Postoperative Crohn’s Disease Endoscopic Recurrence and Is Superior to 6-Mercaptopurine Therapy: An Open-Label, Randomized Controlled Study" Journal of Clinical Medicine 12, no. 24: 7600. https://doi.org/10.3390/jcm12247600

Hirsch, A., Scapa, E., Fliss-Isakov, N., Tulchinsky, H., Itzkowitz, E., Kariv, Y., Ron, Y., Yanai, H., White, I., Yassin, S., Cohen, N. A., Brazovski, E., Dotan, I., & Maharshak, N. (2023). Early Initiation of Adalimumab Significantly Diminishes Postoperative Crohn’s Disease Endoscopic Recurrence and Is Superior to 6-Mercaptopurine Therapy: An Open-Label, Randomized Controlled Study. Journal of Clinical Medicine, 12(24), 7600. https://doi.org/10.3390/jcm12247600